E M Hodson1, J F Knight, N S Willis, J C Craig. 1. Centre for Kidney Research, Royal Alexandra Hospital for Children, PO Box 3515, Parramatta, Sydney, NSW 2124, Australia. Elisah@nch.edu.au
Abstract
AIMS: To determine the benefits and toxicity of different corticosteroid regimes in preventing relapse in steroid responsive nephrotic syndrome. DESIGN: Meta-analysis of randomised controlled trials. SUBJECTS: Twelve trials involving 868 children aged 3 months to 18 years. MAIN OUTCOME MEASURE: Frequency of relapse. RESULTS: A meta-analysis of five trials, which compared two months of prednisone with three months or more in the first episode, showed that the longer duration significantly reduced the risk of relapse at 12-24 months (relative risk 0.73; 95% confidence interval 0.60 to 0.89) without an increase in adverse events. There was an inverse linear relation (relative risk 1.382 (SE 0.215) - 0.133 (SE 0.048) duration; r(2) = 0.66; p = 0.05) between the duration of treatment and risk of relapse. CONCLUSIONS: Children in their first episode of steroid responsive nephrotic syndrome should be treated with prednisone for at least three months, with an increase in benefit being shown for up to seven months of treatment.
AIMS: To determine the benefits and toxicity of different corticosteroid regimes in preventing relapse in steroid responsive nephrotic syndrome. DESIGN: Meta-analysis of randomised controlled trials. SUBJECTS: Twelve trials involving 868 children aged 3 months to 18 years. MAIN OUTCOME MEASURE: Frequency of relapse. RESULTS: A meta-analysis of five trials, which compared two months of prednisone with three months or more in the first episode, showed that the longer duration significantly reduced the risk of relapse at 12-24 months (relative risk 0.73; 95% confidence interval 0.60 to 0.89) without an increase in adverse events. There was an inverse linear relation (relative risk 1.382 (SE 0.215) - 0.133 (SE 0.048) duration; r(2) = 0.66; p = 0.05) between the duration of treatment and risk of relapse. CONCLUSIONS:Children in their first episode of steroid responsive nephrotic syndrome should be treated with prednisone for at least three months, with an increase in benefit being shown for up to seven months of treatment.
Authors: M Abramowicz; H L Barnett; C M Edelmann; I Greifer; O Kobayashi; G C Arneil; B A Barron; G Gordillo-P; N Hallman; H A Tiddens Journal: Lancet Date: 1970-05-09 Impact factor: 79.321
Authors: E Imbasciati; R Gusmano; A Edefonti; P Zucchelli; C Pozzi; C Grassi; M Della Volpe; F Perfumo; P Petrone; M Picca Journal: Br Med J (Clin Res Ed) Date: 1985-11-09
Authors: Eva Cuzzoni; Raffaella Franca; Sara De Iudicibus; Annalisa Marcuzzi; Marianna Lucafò; Marco Pelin; Diego Favretto; Elena Monti; William Morello; Luciana Ghio; Claudio La Scola; Francesca Mencarelli; Andrea Pasini; Giovanni Montini; Giuliana Decorti; Gabriele Stocco Journal: Eur J Clin Pharmacol Date: 2019-08-28 Impact factor: 2.953
Authors: Nynke Teeninga; Joana E Kist-van Holthe; Nienske van Rijswijk; Nienke I de Mos; Wim C J Hop; Jack F M Wetzels; Albert J van der Heijden; Jeroen Nauta Journal: J Am Soc Nephrol Date: 2013-01 Impact factor: 10.121